Multiple Manufacturers

METHOTREXATE

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Multiple Manufacturers

Methotrexate HCPCS:

J9250

HCPCS Code Descriptor:

Methotrexate sodium, 5 mg

Category:

J Code

Methotrexate NDCs:

No actively aligned NDCs found

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Package Type:

Vial

Route of Administration:

Injection

Methotrexate CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Methotrexate:

METHOTREXATE is a medication manufactured by multiple manufacturers and aligned to the J Code: J9250. METHOTREXATE is administered via the injection route of administration.

Methotrexate Sodium is a chemotherapy drug listed under the class of antimetabolites. This medication works by decreasing the growth of certain cells and slowing down the patient’s immune system. Methotrexate can be used to treat skin and joint disorders along with various types of cancer. This medication is administered via intramuscular injection, subcutaneous injection, and can even be administered orally. Methotrexate is a generic drug that is manufactured by Hikma pharmaceuticals, Sicor Pharmaceuticals, Accord Healthcare, Pfizer, Fresenius Kabi, Mylan, and others. There are many patient assistance websites for this medication.

ACCESS PRICING AND MORE BY REGISTERING

J9250 Added Date:

January 1, 1994

J9250 Effective Date:

January 1, 1997

J9250 Termination Date:

April 1, 2024

We have not yet identified a manufacturer source of Methotrexate billing and coding information.
Methotrexate patient assistance information can be found through Azurity Solutions at the URL: https://azuritysolutions.com/patients/xatmep/#product
METHOTREXATE prescribing information can be found at the link below:
Information regarding METHOTREXATE’s side effects can be found at MedlinePlus